AU2951797A - Use of leptin antagonists for the treatment of diabetes - Google Patents

Use of leptin antagonists for the treatment of diabetes Download PDF

Info

Publication number
AU2951797A
AU2951797A AU29517/97A AU2951797A AU2951797A AU 2951797 A AU2951797 A AU 2951797A AU 29517/97 A AU29517/97 A AU 29517/97A AU 2951797 A AU2951797 A AU 2951797A AU 2951797 A AU2951797 A AU 2951797A
Authority
AU
Australia
Prior art keywords
leptin
treatment
insulin
mice
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU29517/97A
Other languages
English (en)
Inventor
Michael Anthony Cawthorne
Valur Emilsson
Yong-Ling Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU2951797A publication Critical patent/AU2951797A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU29517/97A 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes Abandoned AU2951797A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1997/002240 WO1998055139A1 (en) 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes

Publications (1)

Publication Number Publication Date
AU2951797A true AU2951797A (en) 1998-12-21

Family

ID=8166613

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29517/97A Abandoned AU2951797A (en) 1997-06-06 1997-06-06 Use of leptin antagonists for the treatment of diabetes

Country Status (9)

Country Link
EP (1) EP0986397A1 (ja)
JP (1) JP2002504102A (ja)
KR (1) KR20010013414A (ja)
AU (1) AU2951797A (ja)
CA (1) CA2293504A1 (ja)
HU (1) HUP0003428A3 (ja)
IL (1) IL133136A0 (ja)
TR (1) TR199902980T2 (ja)
WO (1) WO1998055139A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP2422807A3 (en) 2004-02-11 2012-05-30 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
SG159551A1 (en) 2005-02-11 2010-03-30 Amylin Pharmaceuticals Inc Gip analog and hybrid polypeptides with selectable properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2010118384A2 (en) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
EP2621515B1 (en) 2010-09-28 2017-03-29 Aegerion Pharmaceuticals, Inc. A chimeric seal-human leptin polypeptide with increased solubility
CN103957926B (zh) 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
CN111529535A (zh) 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
JP6672157B2 (ja) 2013-11-26 2020-03-25 ザ チルドレンズ メディカル センター コーポレーション 肥満を処置するための化合物およびその使用方法
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
PT3509624T (pt) 2016-09-12 2023-08-28 Amryt Pharmaceuticals Inc Métodos de deteção de anticorpos neutralizantes anti-leptina

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU695934B2 (en) * 1995-06-30 1998-08-27 Eli Lilly And Company Methods for treating diabetes

Also Published As

Publication number Publication date
EP0986397A1 (en) 2000-03-22
KR20010013414A (ko) 2001-02-26
JP2002504102A (ja) 2002-02-05
WO1998055139A1 (en) 1998-12-10
HUP0003428A2 (hu) 2001-05-28
IL133136A0 (en) 2001-03-19
CA2293504A1 (en) 1998-12-10
TR199902980T2 (xx) 2000-05-22
HUP0003428A3 (en) 2001-12-28

Similar Documents

Publication Publication Date Title
AU2951797A (en) Use of leptin antagonists for the treatment of diabetes
Yip et al. Functional GIP receptors are present on adipocytes
Song et al. Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation
Roman et al. Central leptin action improves skeletal muscle AKT, AMPK, and PGC1α activation by hypothalamic PI3K-dependent mechanism
Haffner et al. The role of behavioral variables and fat patterning in explaining ethnic differences in serum lipids and lipoproteins
Garcia-Vicente et al. Oral insulin-mimetic compounds that act independently of insulin
AU645076B2 (en) Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
Syed et al. The effect of thyroid hormone on size of fat depots accounts for most of the changes in leptin mRNA and serum levels in the rat
Zhang et al. Aged-obese rats exhibit robust responses to a melanocortin agonist and antagonist despite leptin resistance
Wang et al. Skeletal muscle mRNA for IGF-IEa, IGF-II, and IGF-I receptor is decreased in sedentary chronic hemodialysis patients
US20080020974A1 (en) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x
Wasan et al. Emerging pharmacological approaches to the treatment of obesity
Tessari Changes in protein, carbohydrate, and fat metabolism with aging: possible role of insulin
EP2872124B1 (en) Lipidated peptides as anti-obesity agents
US20040142868A1 (en) Method of treating liver steatosis in a mammal
Alagna et al. Biliopancreatic diversion: long-term effects on gonadal function in severely obese men
IL198296A (en) Reduction of overweight or obesity
US20030007996A1 (en) Therapies for the prevention and treatment of diabetes and obesity
Baltaci et al. Pinealectomy and melatonin administration in rats: their effects on plasma leptin levels and relationship with zinc
JPWO2005042508A1 (ja) 植物由来β３アドレナリン受容体作動性物質およびその利用
US20040048773A1 (en) Use of leptin antagonists for the treatment of diabetes
Miller et al. Rapamycin does not improve insulin sensitivity despite elevated mammalian target of rapamycin complex 1 activity in muscles of ob/ob mice
Hulsey et al. Intracerebroventricular (icv) administration of mouse leptin in rats: behavioral specificity and effects on meal patterns
KR101760565B1 (ko) Tenc1의 활성 억제제를 유효성분으로 포함하는 당뇨병성 근위축증의 예방 또는 치료용 약학적 조성물
US20020002181A1 (en) Use of leptin antagonists for the treatment of diabetes

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted